Samuel Agresta
2020
In 2020, Samuel Agresta earned a total compensation of $1.1M as Chief Medical Officer at Foghorn Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $99,573 |
|---|---|
| Option Awards | $542,224 |
| Salary | $412,000 |
| Total | $1,053,797 |
Agresta received $542.2K in option awards, accounting for 51% of the total pay in 2020.
Agresta also received $99.6K in non-equity incentive plan and $412K in salary.
Rankings
In 2020, Samuel Agresta's compensation ranked 8,403rd out of 13,090 executives tracked by ExecPay. In other words, Agresta earned more than 35.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,403 out of 13,090 | 36th |
Division Manufacturing | 3,574 out of 5,621 | 36th |
Major group Chemicals And Allied Products | 1,448 out of 2,254 | 36th |
Industry group Drugs | 1,260 out of 1,954 | 36th |
Industry Pharmaceutical Preparations | 930 out of 1,459 | 36th |
Source: SEC filing on April 29, 2022.
Agresta's colleagues
We found two more compensation records of executives who worked with Samuel Agresta at Foghorn Therapeutics in 2020.